CXCL7 is a predictive marker of sunitinib efficacy in clear cell renal cell carcinomas

Autor: Sandy Giuliano, Delphine Borchiellini, Sylvie Negrier, Emmanuel Chamorey, Mélanie Guyot, Damien Ambrosetti, Antoine Frangeul, Jean Marc Ferrero, Renaud Schiappa, A. Claren, Renaud Grépin, Arnaud Jacquel, Jocelyn Gal, Nathalie Rioux-Leclercq, Linsay S. Cooley, Gérard Milano, Bernard Escudier, Julien Parola, Andreas Bikfalvi, Gilles Pagès, Ophelie Cassuto, Papa Diogop Ndiaye, Patrick Auberger, Camillo Porta, Julien Viotti, Maeva Dufies
Přispěvatelé: Institut de recherche en santé, environnement et travail (Irset), Université d'Angers (UA)-Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-École des Hautes Études en Santé Publique [EHESP] (EHESP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ), Université d'Angers (UA)-Université de Rennes (UR)-École des Hautes Études en Santé Publique [EHESP] (EHESP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique )
Rok vydání: 2017
Předmět:
Male
0301 basic medicine
Oncology
Cancer Research
Pathology
Indoles
Neutrophils
Nephrectomy
Mice
0302 clinical medicine
Antineoplastic Combined Chemotherapy Protocols
Sunitinib
Prospective Studies
Prospective cohort study
ComputingMilieux_MISCELLANEOUS
Predictive marker
Hazard ratio
Middle Aged
beta-Thromboglobulin
Kidney Neoplasms
3. Good health
Bevacizumab
Killer Cells
Natural
Survival Rate
030220 oncology & carcinogenesis
Female
medicine.drug
medicine.medical_specialty
[SDV.CAN]Life Sciences [q-bio]/Cancer
Antineoplastic Agents
Disease-Free Survival
03 medical and health sciences
Lymphocytes
Tumor-Infiltrating
Internal medicine
Biomarkers
Tumor
medicine
Animals
Humans
Pyrroles
Carcinoma
Renal Cell
Survival rate
Retrospective Studies
Sirolimus
business.industry
Macrophages
Retrospective cohort study
medicine.disease
Clear cell renal cell carcinoma
030104 developmental biology
Neoplasm Grading
business
Neoplasm Transplantation
Zdroj: British Journal of Cancer
British Journal of Cancer, Cancer Research UK, 2017, 117 (7), pp.947-953. ⟨10.1038/bjc.2017.276⟩
British Journal of Cancer, 2017, 117 (7), pp.947-953. ⟨10.1038/bjc.2017.276⟩
ISSN: 1532-1827
0007-0920
DOI: 10.1038/bjc.2017.276
Popis: Sunitinib is one of the first-line standard treatments for metastatic clear cell renal cell carcinoma (ccRCC) with a median time to progression shorter than 1 year. The objective is to discover predictive markers of response to adapt the treatment at diagnosis. Prospective phase 2 multi-centre trials were conducted in ccRCC patients initiating sunitinib (54 patients) or bevacizumab (45 patients) in the first-line metastatic setting (SUVEGIL and TORAVA trials). The plasmatic level of CXCL7 at baseline was correlated with progression-free survival (PFS). The cut-off value of CXCL7 for PFS was 250 ng ml−1. Patients with CXCL7 plasmatic levels above the cut-off at baseline (250 ng ml−1) had a significantly longer PFS (hazard ratio 0.323 (95% confidence interval 0.147–0.707), P=0.001). These results were confirmed in a retrospective validation cohort. The levels of CXCL7 did not influence PFS of the bevacizumab-treated patients. CXCL7 may be considered as a predictive marker of sunitinib efficacy for ccRCC patients.
Databáze: OpenAIRE
Externí odkaz: